

NAVIDEA BIOPHARMACEUTICALS, INC.  
Form SD  
May 29, 2015

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM SD**

**Specialized Disclosure Report**

**NAVIDEA BIOPHARMACEUTICALS, INC.**  
(Exact name of registrant as specified in its charter)

Delaware                                      001-35076                                      31-1080091  
(State or other jurisdiction                                      (Commission File Number) (IRS Employer Identification No.)  
of incorporation or organization)

5600 Blazer Parkway, Suite 200, Dublin, Ohio 43017-7550  
(Address of principal executive offices)                                      (Zip Code)

Erika Gibson, (614) 793-7500  
(Name and telephone number, including area code, of the person to contact in connection with this report.)

Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to  
 December 31, 2014.



## **Section 1 – Conflict Minerals Disclosure**

### **Item 1.01 Conflict Minerals Disclosure**

Navidea Biopharmaceuticals, Inc. (the Company) has evaluated its current product line to determine whether it manufactures or contracts to manufacture any products for which columbite-tantalite (colta), cassiterite, gold, wolframite, or their derivatives are necessary to the functionality of the product. The Company has determined that its Lymphoseek® (technetium Tc 99m tilmanocept) injection product (the Covered Product) contains tin, a derivative metal from the mineral cassiterite.

The Company has conducted a reasonable country of origin inquiry (RCOI) as required by the Dodd-Frank Wall Street Reform and Consumer Protection Act. The Company's RCOI consisted of submitting inquiries to its supplier of the Covered Product. The Company has relied on the certification from an upstream supplier of its supplier that the tin used in the Covered Product did not originate from the Democratic Republic of Congo or an adjoining country. The Company has no reason to believe that this certification is inaccurate. Accordingly, the Company has determined that the tin contained in the Covered Product did not originate from the Democratic Republic of Congo or an adjoining country.

A copy of this Conflict Minerals Disclosure is publicly available at [www.navidea.com](http://www.navidea.com) under "Investors," then "Conflict Minerals Disclosure."

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

Navidea Biopharmaceuticals, Inc.  
(Registrant)

/s/ Brent L. Larson

May 29, 2015

By (Signature and Title)

(Date)

Brent L. Larson

Executive Vice President, Chief Financial Officer,

Treasurer and Secretary